Navigation Links
New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease
Date:6/15/2010

BRUSSELS, June 15 /PRNewswire-FirstCall/ -- New data from a retrospective cohort study showed that up to three quarters of patients with Parkinson's disease (PD) developed gastrointestinal disorders (GID) that can have a substantial adverse effect on major PD-related clinical and health economic outcomes. These data were presented at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010).

"The new retrospective cohort study suggested that the prevalence of gastrointestinal disorders among patients with Parkinson's disease was high, increased over time and had a significant impact on clinical and societal outcomes," said Dr. Florent Richy, Head of Epidemiology, UCB & Adjunct Professor of Epidemiology, University of Liege, Belgium. "Gastrointestinal disorders can impair the onset of symptom relief by Parkinson's disease drugs and these data help us to better understand the prevalence and consequences of such disorders amongst patients diagnosed with Parkinson's disease."

The study found that gastrointestinal disorders in PD patients were associated with significantly higher rates of neuropsychiatric and motor disorders, as well as increased emergency room admissions, number of concurrent drugs and non-PD healthcare costs.

About the Study

The new findings came from a two year matched retrospective cohort study performed on a U.S. database of patient records (Pharmetrics®)* which included demographic, diagnostic, procedural and prescription information. Patients with at least two prior diagnoses of Parkinson's disease and continuous prescriptions of levodopa or dopamine agonists between 1st September 2005 and 1st September 2006 were selected, and health outcomes and health utilization patterns were followed up over a two year period. Outcomes were defined on the basis of a literature review and included neuropsychiatric, motor, urogenital disturbances, healthcare utilization and related costs.

Four hundred and eighty five patients with Parkinson's disease and GID were matched with 485 patients with Parkinson's disease and without GID. In the data cut, GID incidence among patients with Parkinson's disease and no history of GID increased over time, stabilizing at 75% at 92 months.  In addition GID was associated with significantly higher rates of neuropsychiatric and motor disorders, including psychosexual dysfunction (RR=8, p=0.05), anxiety (RR=1.61, p<0.01), depression (RR=1.28, p=0.03), ataxia (RR=1.24, p=0.03), pain (RR=1.29, p<0.01), movement disorders (RR=1.39, p=0.02), urinary incontinence (RR=1.43, p=0.01) and risk of fall (RR=1.44, p=0.03). Emergency room admissions (ratio=1.42, p<0.01), number of concurrent drugs (ratio=1.06, p=0.04) and Parkinson's disease and non-Parkinson's disease healthcare costs (ratios=1.13 and 1.12, p<0.01 respectively) increased during the observation period in the GID patients.

* This study was performed using a licensed IMS Pharmetrics® datacut

Abstract: Gastrointestinal disorders in patients with Parkinson's Disease: A double-edged sword

Richy F1, Gunn A2, Makaroff L3, Gervasoni C4, Helmers S5

1UCB Pharma SA, Brussels, Belgium & University of Liege, Belgium; 2UCB Pharma SA, Brussels, Belgium; 3Business & Development, Life Sciences, Brussels Belgium; 4Keyrus Biopharma, Lasne, Belgium; 5Emory University School of Medicine, Atlanta, US

Poster Session I, June 14th 2010, 0900-1800

For further information

Eimear O Brien, Associate Director, Global CNS Communications

T +32 2 559 9271, eimear.obrien@ucb.com

Andrea Levin / Public Relations Manager, CNS, UCB, Inc.

Office:  770.970.8352 / Mobile: 404.483.7329 / Email: andrea.levin@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
2. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
3. Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting
4. Reaction Progress Kinetic Analysis to Study Organic Reactions: Free On-Demand Online Seminar
5. Study sheds light into the nature of embryonic stem cells
6. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
7. Carolina Conceptions Announces New Egg Freezing Study to Help Women Preserve their Fertility
8. Volcano Announces Positive Clinical Experience With Its Second Generation OCT Catheter, Prepares for U.S. Regulatory Study
9. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
11. AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients Will be Released in Connection With the ASCO Meeting in Chicago, June 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... BARBARA, CALIFORNIA (PRWEB) , ... April 20, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is pleased to announce ... the new established USDM subsidiary “USDM Europe GmbH” based in Germany. , Braemer ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader in ... today that they were named one of the 2017 Top 10 eClinical Trial ... in the pharmaceutical industry. , “We take pride in honoring Parallel6 as one of ...
(Date:4/19/2017)... ... , ... The Vibrating Orifice Aerosol Generator (VOAG) was developed ... of known diameters for research applications such as for calibrating droplet measuring instruments, ... droplets. , The VOAG requires forcing liquid out of an orifice about ...
(Date:4/19/2017)... ... April 19, 2017 , ... ThermaGenix, the PCR Improvement Company, ... to several other early achievements at ThermaGenix, including the business formation and licensing ... ThermaGenix will use proceeds from the Series A-1 round to:, ...
Breaking Biology Technology:
(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
(Date:3/9/2017)... VIEW, Calif. , March 9, 2017 ... 23andMe , the leading personal genetics company, are using ... now provide customers with personalized nutrition plans that consider ... but also genetic markers impacting how their body may ... food decision support platform uses biometrics such as Body ...
(Date:3/7/2017)... CITY , March 7, 2017   HireVue ... help top global companies identify the best talent, faster, ... as Chief Sales Officer (CSO) and Diana Kucer ... appointments round out a seasoned executive team poised to drive ... beyond, building on a year of record bookings in ...
Breaking Biology News(10 mins):